Showing results (131-140 of 150) with videos related to

Sort By:
Pageof 15
Transboundary and Emerging Diseases|December 14, 2011
Isolation of bluetongue virus serotype 1 from Culicoides vector captured in livestock farms and sequence analysis of the viral genome segment-2A I Dadawala, S K Biswas, W Rehman, et al.
Plos One|September 12, 2013
Dynamics of forest malaria transmission in Balaghat district, Madhya Pradesh, IndiaNeeru Singh, Sunil K Chand, Praveen K Bharti, et al.
Scientific Reports|July 9, 2016
Tick holocyclotoxins trigger host paralysis by presynaptic inhibitionKirat K Chand, Kah Meng Lee, Nickolas A Lavidis, et al.
NPJ Regenerative Medicine|November 19, 2021
Combination of human endothelial colony-forming cells and mesenchymal stromal cells exert neuroprotective effects in the growth-restricted newbornKirat K Chand, Jatin Patel, S T Bjorkman, et al.
Lung Cancer (Amsterdam, Netherlands)|February 16, 2015
Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinomaJacques De Grève, Teresa Moran, Marie-Pascale Graas, et al.
The Indian Journal of Medical Research|July 4, 2015
Socio-economic & household risk factors of malaria in tribal areas of Madhya Pradesh, central IndiaRavendra K Sharma, Mrigendra P Singh, Kalyan B Saha, et al.
Lung Cancer (Amsterdam, Netherlands)|November 8, 2017
Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinibLeora Horn, Scott Gettinger, D Ross Camidge, et al.
Stem Cells Translational Medicine|April 27, 2026
Moderate neuroprotection of combination cell therapy in fetal growth restricted newborns at postnatal day 10Kirat K Chand, Kate Beecher, Rachel Nano, et al.
Cancer Discovery|July 31, 2014
Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutationsYelena Y Janjigian, Egbert F Smit, Harry J M Groen, et al.
Cancer|June 19, 2013
Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activationEunice L Kwak, Geoffrey I Shapiro, Seth M Cohen, et al.
Pageof 15